Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ANAB |
---|---|---|
09:32 ET | 4276 | 25.43 |
09:41 ET | 200 | 24.92 |
09:54 ET | 100 | 25.015 |
09:56 ET | 2509 | 25.32 |
09:57 ET | 300 | 25.2998 |
09:59 ET | 2337 | 25.2 |
10:10 ET | 100 | 25.31 |
10:12 ET | 233 | 25.25 |
10:14 ET | 100 | 25.16 |
10:19 ET | 100 | 25.135 |
10:26 ET | 4065 | 25.03 |
10:28 ET | 600 | 25.04 |
10:32 ET | 8355 | 25.21 |
10:33 ET | 100 | 25.12 |
10:35 ET | 5005 | 25.2305 |
10:37 ET | 535 | 25.235 |
10:48 ET | 100 | 25.11 |
10:57 ET | 332 | 25.15 |
11:00 ET | 100 | 25.07 |
11:02 ET | 200 | 25.06 |
11:04 ET | 1694 | 24.965 |
11:08 ET | 100 | 24.995 |
11:13 ET | 100 | 24.9 |
11:18 ET | 456 | 24.82 |
11:24 ET | 200 | 24.66 |
11:26 ET | 100 | 24.67 |
11:27 ET | 100 | 24.67 |
11:29 ET | 100 | 24.58 |
11:31 ET | 100 | 24.56 |
11:33 ET | 100 | 24.64 |
11:36 ET | 100 | 24.51 |
11:38 ET | 100 | 24.53 |
11:40 ET | 517 | 24.63 |
11:42 ET | 500 | 24.65 |
11:44 ET | 232 | 24.65 |
11:47 ET | 100 | 24.58 |
12:02 ET | 355 | 24.58 |
12:07 ET | 1801 | 24.72 |
12:12 ET | 177 | 24.66 |
12:16 ET | 1080 | 24.6408 |
12:27 ET | 816 | 24.627 |
12:34 ET | 700 | 24.94 |
12:36 ET | 200 | 24.95 |
12:39 ET | 200 | 24.99 |
12:41 ET | 333 | 24.965 |
12:48 ET | 100 | 24.965 |
12:54 ET | 200 | 25.01 |
12:56 ET | 1269 | 25.04 |
01:21 ET | 948 | 25.02 |
01:28 ET | 100 | 25.03 |
01:35 ET | 100 | 24.935 |
01:37 ET | 546 | 24.8501 |
01:39 ET | 233 | 24.93 |
02:00 ET | 100 | 24.8 |
02:04 ET | 200 | 24.72 |
02:15 ET | 347 | 24.72 |
02:22 ET | 100 | 24.67 |
02:24 ET | 100 | 24.65 |
02:26 ET | 100 | 24.65 |
02:29 ET | 100 | 24.65 |
02:31 ET | 965 | 24.78 |
02:45 ET | 100 | 24.775 |
02:49 ET | 333 | 24.7 |
02:51 ET | 100 | 24.76 |
02:56 ET | 600 | 24.82 |
03:03 ET | 301 | 24.79 |
03:05 ET | 700 | 24.79 |
03:09 ET | 225 | 24.82 |
03:14 ET | 116 | 24.97 |
03:18 ET | 150 | 24.9606 |
03:20 ET | 100 | 24.91 |
03:21 ET | 100 | 24.91 |
03:27 ET | 348 | 24.88 |
03:32 ET | 100 | 24.87 |
03:34 ET | 100 | 24.83 |
03:38 ET | 734 | 24.845 |
03:41 ET | 505 | 24.86 |
03:43 ET | 700 | 24.845 |
03:45 ET | 604 | 24.77 |
03:48 ET | 1233 | 24.82 |
03:50 ET | 814 | 24.91 |
03:52 ET | 800 | 25.04 |
03:54 ET | 1631 | 24.98 |
03:56 ET | 8725 | 25.1 |
03:57 ET | 6159 | 25.055 |
03:59 ET | 70564 | 25.07 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
AnaptysBio Inc | 684.9M | -4.1x | --- |
Iteos Therapeutics Inc | 649.2M | -4.8x | --- |
PureTech Health PLC | 753.5M | -17.2x | --- |
Stoke Therapeutics Inc | 724.5M | -5.7x | --- |
Taysha Gene Therapies Inc | 577.9M | -2.6x | --- |
Arrivent Biopharma Inc | 673.2M | 0.0x | --- |
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $684.9M |
---|---|
Revenue (TTM) | $23.0M |
Shares Outstanding | 27.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.31 |
EPS | $-6.13 |
Book Value | $3.31 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | 29.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -706.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.